CSL Limited proposes that human plasma holds the potential to save lives. The biopharmaceutical holding company operates through two main subsidiaries: CSL Behring develops plasma-derived and recombinant products used to treat infections, bleeding disorders, and autoimmune diseases, while bioCSL manufactures influenza vaccines that are marketed and sold globally. CSL Biotherapies' Immunohaematology unit manufactures in-vitro diagnostic products to test blood for transfusion and to detect snake venoms in Australia and Papua New Guinea. CSL also has an intellectual property (IP) arm that licenses intellectual property it isn't using to third-parties.